High performance liquid chromatographic determination of etoricoxib in human plasma

被引:0
作者
Shakya, Ashok K. [1 ]
Khalaf, Nooman A. [1 ]
机构
[1] Al Ahliyya Amman Univ, Fac Pharm & Med Sci, Dept Med & Pharmaceut Chem, Amman 19328, Jordan
关键词
etoricoxib; HPLC-UV; plasma; bioanalysis;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A simple, sensitive and reproducible high performance liquid chromatographic (HPLC) has been developed for the analysis of etoricoxib in plasma. This validated method is successfully applied for the estimation of etoricoxib in human volunteers. The HPLC analysis was performed using BDS-Hypersil C-18 (250 mm x 4.6 mm, 5 pm, Thermo electron corporation, USA) column. The mobile phase used was aqueous buffer (containing 0.3 mL triethyl amine (as peak modifier) and 0.4 mL orthophosphoric acid per liter) : acetonitrite (62:38, v/v). The analytes were detected at 284 nm. The total time for a chromatographic separation was ca. 10 min. Extraction of etoricoxib from plasma was carried out using diethylether:dichloromethane (6:4; v/v). The validated quantitation ranges of this method were 15-3200 ng/mL with coefficients of variation of 2.2-5.4 %. In between and within batch precision was 1.3-5.6 and 0.8-6.7 %, respectively. In between and within batch relative error was 0.6-(-4.8) and 0.9-4.7 %, respectively. Stability of etoricoxib in plasma was > 89 %, with no evidence of degradation during sample processing and 45 days storage in a deep freezer at -70 C. This validated method is sensitive and simple with precision of < 6 % and can be used for pharmacokinetic studies and therapeutic drug monitoring.
引用
收藏
页码:5241 / 5250
页数:10
相关论文
共 11 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]   Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation [J].
Bräutigam, L ;
Nefflen, JU ;
Geisslinger, G .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 788 (02) :309-315
[3]   Etoricoxib [J].
Cochrane, DJ ;
Jarvis, B ;
Keating, GM .
DRUGS, 2002, 62 (18) :2637-2651
[4]   Characterization of etoricoxib, a novel, selective COX-2 inhibitor [J].
Dallob, A ;
Hawkey, CJ ;
Greenberg, H ;
Wight, N ;
De Schepper, P ;
Waldman, S ;
Wong, P ;
DeTora, L ;
Gertz, B ;
Agrawal, N ;
Wagner, J ;
Gottesdiener, K .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) :573-585
[5]   RISK FOR SERIOUS GASTROINTESTINAL COMPLICATIONS RELATED TO USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS - A METAANALYSIS [J].
GABRIEL, SE ;
JAAKKIMAINEN, L ;
BOMBARDIER, C .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (10) :787-796
[6]  
*M SHARP DOHM LIM, 2002, ARC ET TABL SUMM PRO
[7]   High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection [J].
Matthews, CZ ;
Woolf, EJ ;
Lin, L ;
Fang, W ;
Hsieh, J ;
Ha, S ;
Simpson, R ;
Matuszewski, BK .
JOURNAL OF CHROMATOGRAPHY B, 2001, 751 (02) :237-246
[8]   Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction [J].
Ramakrishna, NVS ;
Vishwottam, KN ;
Wishu, S ;
Koteshwara, M .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 816 (1-2) :215-221
[9]   Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS [J].
Rose, MJ ;
Agrawal, N ;
Woolf, EJ ;
Matuszewski, BK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (02) :405-416
[10]   A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and vaidecoxib in human plasma [J].
Werner, U ;
Werner, D ;
Hinz, B ;
Lambrecht, C ;
Brune, K .
BIOMEDICAL CHROMATOGRAPHY, 2005, 19 (02) :113-118